Drug intelligence / Profile preview

estradienolone

Development stage
Preclinical
Lead developer
McGill University
Modality
Small Molecules
Administration
Parenteral
01

Overview

Estradienolone (also referred to as estradiol dienolone) is a novel endogenous 19-nor steroid hormone identified in pregnant women. It is an isomer of estradiol that acts as a natural inverse agonist of the estrogen-related receptors alpha (ERRα) and gamma (ERRγ), directly interacting with these receptors to inhibit their transcriptional activity. Estradienolone has demonstrated strong anti-mitogenic properties, inhibiting the growth of both estrogen receptor-positive and estrogen receptor-negative breast cancer cells in a dose-dependent manner while showing minimal effect on normal epithelial breast cells. It also binds with high affinity to the progesterone receptor and sex hormone-binding globulin (SHBG). The compound is being investigated by researchers at McGill University and the University of Montreal as a potential therapeutic strategy for breast cancer.

Other names
17β-hydroxy-1,5-estradiene-3-one17β-hydroxy-19-nor-androsta-1,5-dien-3-oneestradiol dienoloneestradienolone
02

Targets

PR (Progesterone receptor)SHBG (Sex hormone-binding globulin)

Beyond the preview

Go deeper on estradienolone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on estradienolone.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call